All Stories

  1. Comparative efficacy of stereotactic body radiotherapy and percutaneous radiofrequency ablation for oligometastatic liver disease—radiation oncologists’ perspective and practice guideline
  2. Determining Optimal Fractionation of Neoadjuvant Radiation in Low-Risk, Early-Stage Breast Cancer—Randomized SIGNAL Clinical Trial
  3. A comparison of contrast-to-noise ratio of liver tumors between dynamic contrast-enhanced CT and respiration-tracked 4D-CT for radiotherapy targeting
  4. Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort
  5. Oral relugolix for the treatment of advanced prostate cancer
  6. Practical Aspects of Delivering Radiation for Polymetastatic Disease
  7. Ultrahypofractionated Versus Conventionally Fractionated Whole-pelvis Radiotherapy in Prostate Cancer: A Randomized Clinical Trial
  8. The Dilemma of Choice: Options for Nonoperable Hepatocellular Carcinoma Management
  9. 1477P Overall survival among 4913 patients with hepatocellular carcinoma treated with external beam radiation therapy: Individual patient data outcomes from a multinational cohort
  10. Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial
  11. Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI)
  12. Comparison of CellSearch versus Parsortix circulating tumor cell enumeration and molecular characterization: A pilot study in metastatic prostate cancer patients
  13. 1634 Is hypofractionated whole-pelvis RT (WPRT) as well tolerated as conventional WPRT in prostate cancer? Analysis of the Hope trial primary endpoint
  14. Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis
  15. Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis
  16. Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9).
  17. Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma
  18. Enteral and parenteral nutrition in patients with cancer: complication rates compared—updated systematic review and meta-analysis
  19. Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial
  20. Left atrial myxoma metastasizing to the brain: a case report and review of literature
  21. Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase 1 Study of Stereotactic Ablative Radiation Therapy for Polymetastatic Disease
  22. Helical Tomotherapy Versus 3-Dimensional Conformal Radiation Therapy in High-Risk Prostate Cancer: A Phase 3 Randomized Controlled Trial
  23. Acute Cardiac Inflammation 1-Year after Left-Sided Breast Cancer Radiotherapy Assessed with Hybrid PET/MRI
  24. Prognostic Index for Liver Radiation (PILiR)
  25. A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol
  26. 423P Marginalization and factors associated with early mortality among patients diagnosed with de novo metastatic breast cancer in Ontario, Canada
  27. Diagnostic CT-Enabled Planning (DART): Results of a Randomized Trial in Palliative Radiation Therapy
  28. Prognostic Index for Liver Radiation (PILiR)
  29. Barrier films or dressings for the prevention of acute radiation dermatitis in breast cancer: a systematic review and network meta-analysis
  30. Malignant Phyllodes Tumors of the Breast With Rhabdomyosarcomatous Differentiation: A Case Report and Literature Review
  31. Is Ultrahypofractionated Whole Pelvis Radiation Therapy (WPRT) as Well Tolerated as Conventionally Fractionated WPRT in Patients With Prostate Cancer? Early Results From the HOPE Trial
  32. A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients with Up to 10 Oligometastases and a Synchronous Primary Tumor (SABR-SYNC): Study Protocol
  33. The Current Role of Radiation in the Management of Cholangiocarcinoma—A Narrative Review
  34. 315: ARREST – A phase I study of SABR for poly-metastatic disease.
  35. Dose-response of localized renal cell carcinoma after stereotactic body radiation therapy: A meta-analysis
  36. Immunotherapy and Radiation Therapy Sequencing in Breast Cancer: A Systematic Review
  37. Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidance for the prevention of breast cancer-related arm lymphoedema (BCRAL): international Delphi consensus-based recommendations
  38. Stereotactic Body Radiation Therapy (SBRT) Versus Transarterial Chemoembolization (TACE) for Treatment Of Hepatocellular Carcinoma: a Meta-Analysis of Propensity Matched Studies
  39. Re: Deng and Heybati
  40. Diagnostic CT-Enabled Radiation Therapy (DART): Results of a Randomized Trial for Palliative Radiation Therapy
  41. Palliative radiotherapy for hepatic tumors: a narrative review of indications and recommendations
  42. Treatment modalities to manage hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and meta-analysis
  43. Complication Avoidance of Reconstruction Implant Radiation Therapy (CARIT): A Retrospective Case-Cohort Analysis
  44. Long-Term Outcomes of NRG/RTOG 0126, a Randomized Trial of High Dose (79.2 Gy) vs. Standard Dose (70.2 Gy) Radiation Therapy (RT) for Men with Localized Prostate Cancer
  45. Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI): Acute Toxicity Results
  46. Radiotherapy for Liver Cancer: An International Multi-Centre Pooled Analysis of 925 Cases
  47. Treatment Modalities to Manage Hepatocellular Carcinoma Patients with Portal Vein Thrombus: A Systematic Review and Meta-Analysis
  48. 112 Is Hypofractionated Whole-Pelvis Radiotherapy (WPRT) as Well Tolerated as Conventionally Fractionated WPRT in Prostate Cancer Patients? An Early Analysis of the Hope-Trial
  49. 57 Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST) - a Phase 1 Study of SABR for Poly-Metastatic Disease
  50. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis
  51. What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment
  52. Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial
  53. PET/MRI Assessment of Acute Cardiac Inflammation 1 Month After Left-Sided Breast Cancer Radiation Therapy
  54. A Rare Case of Recurrent Cutaneous Non-Hodgkin’s Lymphoma in the Extremity: Long-Term Follow-Up and Review of the Literature Written With the Assistance of ChatGPT
  55. Are Radiation Target Volumes for Postmastectomy Radiation Therapy Too Large? Initial Report of the Complication Avoidance of Reconstruction Implant Radiation Therapy (CARIT) Study
  56. NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC).
  57. Use of artificial intelligence for cancer clinical trial enrollment: a systematic review and meta-analysis
  58. NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937)
  59. Assessing Acute Cardiac Inflammation after Left-Sided Breast Cancer Radiotherapy with Hybrid PET/MRI (RICT-BREAST)
  60. Development of a Support Vector Machine-Based Tool for Survival Prediction after Stereotactic Body Radiotherapy for Liver Metastases Using Multi-Institutional Data
  61. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes
  62. Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis
  63. Does stereotactic body radiation improve outcomes compared to conventional radiation for liver cancer patients?
  64. Dosimetric Planning Comparison for Left-Sided Breast Cancer Radiotherapy: The Clinical Feasibility of Four-Dimensional-Computed Tomography-Based Treatment Planning Optimization
  65. Assessing Acute Cardiac Inflammation One Month after Left-sided Breast Cancer Radiotherapy with Hybrid PET/MRI
  66. OC-0104 Stereotactic radiation for treatment of oligometastases (SABR-COMET) – Extended long-term outcomes
  67. Comparing treatment modalities for hepatocellular carcinoma: the value of network meta-analyses
  68. Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications
  69. Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126
  70. Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer – a systematic review and network meta-analysis of survival data
  71. Dose Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes From the NRG Oncology/RTOG 0815 Randomized Trial
  72. Re-Evaluating the Toxicity of Radiotherapy in Patients With Collagen Vascular Disease: A Meta-Analysis of Propensity Score Studies
  73. Prophylaxis and treatment of cancer-related dyspnea with pharmacologic agents: A systematic review and network meta-analysis
  74. Weight changes of younger and older early breast cancer patients—a meta regression
  75. Cancer-related fatigue—pharmacological interventions: systematic review and network meta-analysis
  76. Esophageal Cancer Radiotherapy Dose Escalation Meta Regression Commentary: “High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis”
  77. Abstract 2701: Molecular profiling to assess the immune response to neoadjuvant SABR in early breast cancer
  78. Redefining postmastectomy radiation contouring in the era of immediate breast reconstruction: An accurate assessment of local recurrence risk
  79. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019
  80. Weight Change of Younger and Older Early Breast Cancer Patients – A Meta Regression
  81. Intrafraction motion monitoring to determine PTV margins in early stage breast cancer patients receiving neoadjuvant partial breast SABR
  82. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?
  83. Cost Minimization Analysis of Hypofractionated Radiotherapy
  84. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature
  85. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients
  86. The addition of radiofrequency ablation for patients receiving sorafenib: new evidence for a new standard?
  87. Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging
  88. Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trials
  89. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Randomized Trial
  90. Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial
  91. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
  92. 8: Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-Comet Randomized Trial
  93. The Effect of Registration on Voxel-Wise Tofts Model Parameters and Uncertainties from DCE-MRI of Early-Stage Breast Cancer Patients Using 3DSlicer
  94. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients
  95. Corrigendum to “Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis” [Radiother Oncol 141 (2019) 56–61]
  96. Patterns of Failure Observed in the 2-Step Institution Credentialing Process for NRG Oncology/Radiation Therapy Oncology Group 1005 (NCT01349322) and Lessons Learned
  97. Consensus Statement on Tumour Bed Localization for Radiation after Oncoplastic Breast Surgery
  98. How robust are the results of one of the first positive trials exploring hydroxychloroquine for treatment of COVID-19?
  99. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
  100. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy
  101. DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR
  102. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis
  103. Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis
  104. Correction to: Enteral and parenteral nutrition in cancer patients, a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis
  105. Enteral and parenteral nutrition in cancer patients, a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis
  106. Inter-rater reliability in performance status assessment between clinicians and patients: a systematic review and meta-analysis
  107. Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial
  108. Recurrence and Mortality after Breast-Conserving Surgery without Radiation
  109. Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis
  110. Symptoms Predictive of Overall Quality of Life Using the Edmonton Symptom Assessment Scale in Breast Cancer Patients Receiving Radiotherapy
  111. A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis
  112. 132 Prognostic Index for Localized Liver Radiation - Metastatic (PILLiR-M): Development and Analysis of a Clinical Prognostic Tool to Improve Patient Selection for Liver Directed Radiotherapy for Liver Metastases
  113. 156 Validation and Inter-Rater Reliability of Two Metrics Used as Predictors of Heart Dose in Patients Treated with Adjuvant Radiotherapy to the Left Breast
  114. 34 Dosimetric Comparison and Toxicity Analysis of Stereotactic Radiotherapy for High-Risk Prostate Cancer
  115. 91 Quality of Life Outcomes After Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial
  116. Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis
  117. Symptom clusters in patients with breast cancer receiving radiation therapy
  118. Dosimetric Comparison and Toxicity Analysis of Stereotactic Radiotherapy for High-Risk Prostate Cancer
  119. Prognostic Index for Localized Liver Radiation – Hepatocellular Carcinoma (PILLiR-HCC): Development and Analysis of a Clinical Prognostic Tool to Improve Patient Selection for Liver Directed Radiotherapy in Patients with Hepatocellular Carcinoma
  120. Prognostic Index for Localized Liver Radiation – Metastatic (PILLiR-M): Development and Analysis of a Clinical Prognostic Tool to Improve Patient Selection for Liver Directed Radiotherapy for Liver Metastases
  121. Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) vs. Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial
  122. Validation and Inter-Rater Reliability of Two Metrics Used As Predictors of Heart Dose in Patients Treated with Adjuvant Radiotherapy to the Left Breast
  123. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
  124. Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Post-lumpectomy Patients with Breast Cancer Receiving Adjuvant Radiation Therapy
  125. Stereotactic Image-Guided Neoadjuvant Ablative Single-Dose Radiation, then Lumpectomy, for Early Breast Cancer: The Signal Prospective Single-Arm Trial of Single-Dose Radiation Therapy
  126. Prostate Cancer, Gender Identity, and Testosterone Replacement Therapy in Klinefelter Syndrome: A Case Report and Literature Review
  127. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
  128. Reducing the dose of gadolinium-based contrast agents for DCE-MRI guided SBRT: The effects on inter and intra observer variability for preoperative target volume delineation in early stage breast cancer patients
  129. Prognostic Significance of Tumor Location for Liver Cancer Radiotherapy
  130. Appropriate Treatment Receipt after Breast-Conserving Surgery
  131. Radiobiologically Guided Radiation Therapy in Large Primary and Metastatic Hepatic Lesions
  132. Stereotactic ablative radiotherapy for oligometastatic cancers: Efficacy and toxicity results from the randomized SABR-COMET Trial
  133. Results of a Prospective Cohort Trial: Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy (SIGNAL) for Early-Stage Breast Cancer
  134. Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial
  135. Phase II Trial of Pure Hypofractionated Radiotherapy in the Treatment of Localized Carcinoma of the Prostate
  136. Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer
  137. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer
  138. Patient-perceived barriers to radiation therapy for breast cancer
  139. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies
  140. The Utility of Penile Bulb Contouring to Localise the Prostate Apex as Compared to Urethrography
  141. Lessons Learned From the Two-Step QA Process in NRG Oncology/RTOG 1005, A Phase 3 Trial for Early-Stage Breast Cancer
  142. Advances in external beam stereotactic body radiotherapy: principle concerns in implementing a liver radiation program
  143. Reducing Patient Waiting Times for Radiation Therapy and Improving the Treatment Planning Process: a Discrete-event Simulation Model (Radiation Treatment Planning)
  144. EP-1365: Pure Hypofractionated Radiotherapy for the Treatment of Low- to Intermediate-Risk Prostate Cancer
  145. Potential benefit of rotational radiation therapy
  146. A multivariable model to predict survival for patients with hepatic carcinoma or liver metastasis receiving radiotherapy
  147. Strategies to tackle the challenges of external beam radiotherapy for liver tumors
  148. Stereotactic Body Radiotherapy
  149. Computed tomography imaging assessment of postexternal beam radiation changes of the liver
  150. Postediting prostate magnetic resonance imaging segmentation consistency and operator time using manual and computer-assisted segmentation: multiobserver study
  151. Predicting which patients actually receive radiation following breast conserving therapy in Canadian populations
  152. 92: Identification of Patients that will not Benefit from Hepatic Radiation
  153. Sci‐Fri AM: MRI and Diagnostic Imaging ‐ 03: The influence of sampling percentage in deformable registration on kinetic model analysis results in DCE‐MRI of the breast
  154. Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions
  155. A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy
  156. Evaluation of Health Economics in Radiation Oncology: A Systematic Review
  157. A phase II trial to evaluate single-dose stereotactic body radiation therapy (SBRT) prior to surgery for early-stage breast carcinoma: SIGNAL (stereotactic image-guided neoadjuvant ablative radiation then lumpectomy) trial
  158. A Systematic Review of Health Economic Evaluations in Radiation Oncology
  159. Bowel and Bladder Function of Men on a Phase 3 Randomized Study of High Versus Standard Dose of 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer
  160. Concurrent or Sequential Hormonal and Radiation Therapy in Breast Cancer: A Literature Review.
  161. Abscopal Effects: Case Report and Emerging Opportunities
  162. How has SBRT progressed in different countries and what this can teach us in the future
  163. The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy
  164. A case-control, mono-center, open-label, pilot study to evaluate the feasibility of therapeutic touch in preventing radiation dermatitis in women with breast cancer receiving adjuvant radiation therapy
  165. A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer
  166. Dosimetric Comparison of Volumetric Modulated Arc Therapy, Tomotherapy and Intensity Modulated Radiation Therapy for Radiation Dose Escalation of Hepatic Malignancies
  167. A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer.
  168. Initial Results of a Phase 3 Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (RTOG 0126)
  169. Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma
  170. In Regard to Parikh et al
  171. Spatially varying accuracy and reproducibility of prostate segmentation in magnetic resonance images using manual and semiautomated methods
  172. Variation in Clinical Target Volumes for Post-prostatectomy Patients and Effect on Normal Tissue Complication Probability
  173. Increased Plasma IL-17F Levels in Rheumatoid Arthritis Patients Are Responsive to Methotrexate, Anti-TNF, and T Cell Costimulatory Modulation
  174. Dosimetric Comparison of Volumetric Modulated Arc Therapy, Tomotherapy, and Intensity Modulated Radiation Therapy for Radiation Dose Escalation of Hepatic Malignancies
  175. Identification of Patients With Liver Cancer That Will Not Benefit From Radiation
  176. Feasibility of Preoperative Volumetric-Modulated Arc Therapy for Early Stage Breast Cancer
  177. Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Women with Breast Cancer Receiving Adjuvant Radiation Therapy
  178. Assessment of contrast enhanced respiration managed cone-beam CT for image guided radiotherapy of intrahepatic tumors
  179. Dynamic contrast enhanced CT aiding gross tumor volume delineation of liver tumors: An interobserver variability study
  180. Effects of registration error on parametric response map analysis: a simulation study using liver CT-perfusion images
  181. Graded-threshold parametric response maps: towards a strategy for adaptive dose painting
  182. PO-0705: Phase I/II study of image-guided and radiobiologically guided radiotherapy for hepatic lesions
  183. PO-0976: Feasibility of preoperative volumetric-modulated arc therapy for early stage breast cancer
  184. Phase 1 Study of Image-Guided and Radiobiologically-Guided Stereotactic Body Radiation Therapy for Hepatic Lesions
  185. Prostate Cancer Brachytherapy: Does Real-Time Dynamic Ultrasound Planning With Continuous Feedback Produce Dosimetry Predictive of the Subsequent CT/MRI Dose Distribution?
  186. Cost-minimization analysis: should partial breast irradiation be utilized over whole breast irradiation assuming equivalent clinical outcomes?
  187. Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours
  188. Prediction and Reduction of Motion Artifacts in Free-Breathing Dynamic Contrast Enhanced CT Perfusion Imaging of Primary and Metastatic Intrahepatic Tumors
  189. Automated IMRT planning with regional optimization using planning scripts
  190. Improving the Efficiency of Radiation Therapy Delivery by Resource Optimization
  191. Gleason Pattern 5 is Associated With an Increased Risk for Metastasis Following Androgen Deprivation Therapy (ADT) and Radiation: An Analysis of RTOG 9202 and 9902
  192. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
  193. Fitness to Drive in Patients with Brain Tumours: The Influence of Mandatory Reporting Legislation on Radiation Oncologists in Canada
  194. An international survey on liver metastases radiotherapy
  195. Radiotherapy for Liver Metastases: A Review of Evidence
  196. The Impact of Post-Mastectomy Radiation Therapy on Male Breast Cancer Patients—A Case Series
  197. Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy
  198. Development of an Automated Atlas-based Segmentation Technology Assessment Methodology
  199. Fitness to Drive in Patients with Brain Tumors: The Influence of Mandatory Reporting Legislation in Canada
  200. Case-cohort study to determine the value of therapeutic touch in preventing radiation dermatitis.
  201. A Phase II Trial of Arc-Based Hypofractionated Intensity-Modulated Radiotherapy in Localized Prostate Cancer
  202. Phase I Trial of Simultaneous In-Field Boost With Helical Tomotherapy for Patients With One to Three Brain Metastases
  203. SU-E-U-07: Comparison of 3D Ultrasound Prostate Localization with Electronic Portal Imaging of Fiducial Markers
  204. TH-E-110-08: Free Breathing Hepatic CT Perfusion with Automatic a Posteriori Motion Correction
  205. Brachytherapy with permanent gold grain seeds for squamous cell carcinoma of the lip
  206. Technology assessment of automated atlas based segmentation in prostate bed contouring
  207. Radiation recall dermatitis due to gemcitabine does not suggest the need to discontinue chemotherapy
  208. Effective and cost-effective clinical trial recruitment strategies for postmenopausal women in a community-based, primary care setting
  209. SU-GG-I-101: 3D Segmentation and Rigid Registration for Minimizing Breathing Motion Effects in Liver CT Perfusion
  210. A phase II trial of arc-based hypofractionated IMRT in localized prostate cancer.
  211. 188 THE CLINICAL IMPACT OF VARIATION IN CLINICAL TARGET VOLUMES FOR POST-PROSTATECTOMY PATIENTS
  212. Systematic review of dose–volume parameters in the prediction of esophagitis in thoracic radiotherapy
  213. TH‐C‐304A‐09: Semi‐Automatic Respiratory Motion Correction for Liver CT Perfusion
  214. Salvage radiotherapy following radical prostatectomy
  215. Mathematical modeling of liver metastases tumour growth and control with radiotherapy
  216. Inter- and Intra-observer Agreement in Clinical Target Volumes for Post-prostatectomy Patients
  217. Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer
  218. Poster - Thurs Eve-04: Mathematical modeling of liver metastases tumour growth and control with radiotherapy
  219. Brachytherapy with permanent gold grain seeds for squamous cell carcinoma of the lip
  220. Gabapentin for the treatment of menopausal hot flashes
  221. Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer
  222. Hepatic Lesion Radiotherapy: A New Option?
  223. Correlation of Clinically Significant Radiation Esophagitis With Dose-Volume Histogram Parameters in Lung Cancer
  224. Systematic review of baseline low-dose CT lung cancer screening
  225. Development and psychometric properties of the Prostate Cancer Radiation Toxicity Questionnaire
  226. A Prospective Evaluation of Helical Tomotherapy
  227. Psychometric properties of a prostate cancer radiation late toxicity questionnaire
  228. Oxybutynin for refractory hot flashes in cancer patients
  229. Minimal decrease in hot flashes desired by postmenopausal women in family practice
  230. 2840
  231. 2322
  232. 2327
  233. Clinical Implementation of Adaptive Helical Tomotherapy: A Unique Approach to Image-Guided Intensity Modulated Radiotherapy
  234. A comparison of prostate IMRT and helical tomotherapy class solutions
  235. 23 An NTCP formalism accounting for complications from radiation treatment and tumour invasion
  236. 107 Effectiveness of ditropan for the treatment of hot flashes in cancer patients: A single centre retrospective review
  237. 113 Outcome analysis of prostate cancer patients presenting with PSA >50 Ng/MI
  238. 156 Gynaecologic HDR Interstitial Brachytherapy: The Role of Radiation Oncology Nursing in Multi-disciplinary Care
  239. 190 A comparison of optical infrared camera and spirometry guided respiratory gating for liver radiotherapy
  240. 237 Regional recurrence in women with high risk stages I to IIb breast cancer after lumpectomy, systemic therapy, and breast only radiotherapy
  241. 33 Hypofractionated prostate arc radiotherapy using ultrasound localization
  242. 82 Comparing two strategies of dynamic intensity modulated radiation therapy using helical tomotherapy versus 3D conformal radiation therapy in the hypofractionated treatment of the pelvis in high risk prostate cancer
  243. Prostate contouring uncertainty in megavoltage computed tomography images acquired with a helical tomotherapy unit during image-guided radiation therapy
  244. TH‐C‐ValB‐01: Prostate Contouring Uncertainty in Mega‐Voltage Computed Tomography (MVCT) Images Acquired with a Helical Tomotherapy Unit During Image‐Guided Radiation Therapy (IGRT)
  245. Assessing the Prognostic Significance of Transrectal Ultrasound Extracapsular Extension in Prostate Cancer
  246. 22 Development find Psychometric Properties of the Prostate Cancer Radiation Toxicity Questionnaire
  247. 104 An interactive three-dimensional atlas of nodal topography for radiotherapy treatment planning education
  248. 12 Evaluation of 3D-ultrasound Image Guided Radiotherapy in Prostate Cancer Compared to Implanted Fiducial Markers
  249. 27 Accuracy of Prostate Cancer Staging at a Tertiary Care Cancer Centre
  250. 55 Limits and limitations of MRI and CT lymphatic target volume delineation: Analysis of the visible human high resolution anatomic data sets
  251. 87 Application of helical tomotherapy to palliative and radical genitourinary malignancies
  252. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer
  253. Intensity-modulated arc therapy for treatment of high-risk endometrial malignancies
  254. Follicular Dendritic Cell Sarcoma: Case Report and Review of Current Management Principles
  255. Prognostic factors in brain metastases: can we determine patients who do not benefit from whole-brain radiotherapy?
  256. Prediction of radiation pneumonitis by dose–volume histogram parameters in lung cancer—a systematic review
  257. Megavoltage Computed Tomography Imaging: A Potential Tool to Guide and Improve the Delivery of Thoracic Radiation Therapy
  258. Breast Edema during Radiotherapy Can Result in Underdosing
  259. Impact of urethrography on geometric uncertainty in prostate cancer radiotherapy
  260. Megavoltage CT imaging for adaptive helical tomotherapy of lung cancer
  261. 150 Small cell carcinoma of the head and neck: experience of a single comprehensive cancer centre
  262. 183 Intensity modulated arc therapy and carboplatin/paclitaxel chemotherapy for treatment of high-risk endometrial malignancies
  263. 891 Impact of urethrography in high-precision prostate cancer radiotherapy
  264. Consolidative abdomino-pelvic radiotherapy following surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer
  265. Prognostic factors in brain metastases: can we determine predictors of early death
  266. Hodgkin's disease — stage ia and iia: omission of pelvic irradiation in clinically and laparotomy staged patients